N-((5-chloro-8-hydroxyquinolin-7-yl)(furan-2-yl)methyl)-2-phenoxyacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((5-chloro-8-hydroxyquinolin-7-yl)(furan-2-yl)methyl)-2-phenoxyacetamide
• 英文别名: N-[(5-chloro-8-hydroxyquinolin-7-yl)(2-furyl)methyl]-2-phenoxyacetamide；N-[(5-chloro-8-hydroxyquinolin-7-yl)-(furan-2-yl)methyl]-2-phenoxyacetamide
• 化学式: C₂₂H₁₇ClN₂O₄
• 分子量: 408.841
• InChiKey: LRBZWXYIDAWDGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] INHIBITORS OF JMJD2C AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS DE JMJD2C UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：DAVID GLADSTONE INST

  公开号：WO2015167874A1

  公开（公告）日：2015-11-05

  The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.

  本公开提供了化合物、制药组合物和相关方法，用于治疗癌症，例如去势抵抗性前列腺癌（CRPC）。具体而言，本公开提供一系列8-羟基喹啉衍生物，其对雄激素非依赖性前列腺癌细胞具有细胞毒性作用。
• 8-Hydroxyquinoline compounds and methods thereof
  申请人：Bursavich Matthew G.

  公开号：US20080269213A1

  公开（公告）日：2008-10-30

  The present invention relates to 8-Hydroxyquinoline Compounds; compositions comprising an 8-Hydroxyquinoline Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, malignant neoplasm, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease or comprising administering an effective dose of an 8-Hydroxyquinoline Compound to a mammal in need thereof.

  本发明涉及8-羟基喹啉化合物；包含一种8-羟基喹啉化合物的组合物；以及治疗或预防金属蛋白酶相关疾病的方法，例如关节炎、骨关节炎、恶性肿瘤、类风湿性关节炎、哮喘、慢性阻塞性肺病、动脉粥样硬化、年龄相关性黄斑变性、心肌梗死、角膜溃疡、眼表疾病、肝炎、主动脉瘤、肌腱炎、中枢神经系统疾病、异常伤口愈合、血管生成、再狭窄、肝硬化、多发性硬化症、肾小球肾炎、移植物抗宿主病、糖尿病、炎性肠病、休克、椎间盘退化、中风、骨质疏松或牙周疾病；或者包括向需要的哺乳动物施用有效剂量的8-羟基喹啉化合物。
• INHIBITORS OF JMJD2C AS ANTICANCER AGENTS
  申请人：The J. David Gladstone Institutes

  公开号：EP3137079A1

  公开（公告）日：2017-03-08
• Inhibitors of JMJD2C as Anticancer Agents
  申请人：The J. David Gladstone Institutes

  公开号：US20170044107A1

  公开（公告）日：2017-02-16

  The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells.
• US7947712B2
  申请人：——

  公开号：US7947712B2

  公开（公告）日：2011-05-24